for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioDelivery Sciences International, Inc.

BDSI.OQ

Latest Trade

6.21USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.84

 - 

6.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Biodelivery Sciences International Expects Full Year 2020 Total Company Net Sales Of $165 Million - $175 Million

Nov 12 (Reuters) - BioDelivery Sciences International Inc <BDSI.O>::BIODELIVERY SCIENCES REPORTS STRONG THIRD QUARTER RESULTS, RAISES FULL YEAR 2019 AND PROVIDES 2020 NET SALES EXPECTATIONS.Q3 REVENUE $30.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $28.3 MILLION.SEES FY 2019 SALES $105 MILLION TO $110 MILLION.PROVIDES FULL YEAR 2020 BELBUCA NET SALES EXPECTATIONS OF $150 - $160 MILLION.PROVIDES FULL YEAR 2020 TOTAL COMPANY NET SALES EXPECTATIONS OF $165 - $175 MILLION.QTRLY EARNINGS PER SHARE $0.00.AS OF SEPTEMBER 30, 2019, CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $55.9 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.02 -- REFINITIV IBES DATA.

Biodelivery Sciences International Q2 GAAP Loss Per Share $0.13

Aug 8 (Reuters) - BioDelivery Sciences International Inc <BDSI.O>::BIODELIVERY SCIENCES REPORTS STRONG SECOND QUARTER 2019 RESULTS AND RAISES NET SALES EXPECTATIONS.Q2 GAAP LOSS PER SHARE $0.13.Q2 REVENUE $29.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $24.7 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.06 -- REFINITIV IBES DATA.SEES FY 2019 SALES $101 MILLION TO $105 MILLION.RAISES LONG-TERM COMBINED NET SALES EXPECTATIONS FOR BELBUCA AND SYMPROIC TO $425 - $500 MILLION.RAISES FULL-YEAR BELBUCA NET SALES EXPECTATIONS TO $90 - $93 MILLION.ANTICIPATES HAVING POSITIVE OPERATING CASH FLOW BY Q4.

Biodelivery Sciences International Files For Mixed Shelf Of Up to $125 Mln

July 29 (Reuters) - BioDelivery Sciences International Inc <BDSI.O>::BIODELIVERY SCIENCES INTERNATIONAL INC FILES FOR MIXED SHELF OF UPTO $125 MILLION - SEC FILING.BIODELIVERY SCIENCES INTERNATIONAL INC SAYS IN ADDITION, SELLING STOCKHOLDER OFFERING 12.8 MILLION SHARES OF CO'S COMMON STOCK.

Biopharma Credit Entered Into A Definitive Senior Secured Term Loan Agreement

May 29 (Reuters) - BioDelivery Sciences International Inc <BDSI.O>::BIOPHARMA CREDIT PLC - ENTERED INTO A DEFINITIVE SENIOR SECURED TERM LOAN AGREEMENT FOR UP TO US$80 MILLION WITH BIODELIVERY SCIENCES.BIOPHARMA CREDIT - BPCR ACQUIRED 5,000,000 BDSI SHARES AT US$5.00 EACH FOR A TOTAL COST OF US$25 MILLION IN A PUBLIC OFFERING THAT PRICED ON 11 APRIL 2019.BIOPHARMA CREDIT PLC - LOAN WILL MATURE IN MAY 2025 AND BEARS INTEREST AT LIBOR PLUS 7.5%, ALONG WITH 2% ADDITIONAL CONSIDERATION.

BioDelivery Sciences Strengthens Financial Position With Debt Refinancing

May 28 (Reuters) - BioDelivery Sciences International Inc <BDSI.O>::BIODELIVERY SCIENCES STRENGTHENS FINANCIAL POSITION WITH DEBT REFINANCING.BIODELIVERY SCIENCES INTERNATIONAL INC - NEW AGREEMENT IS CASH FLOW ACCRETIVE, LOWERS COST OF CAPITAL AND EXTENDS DEBT MATURITY.BIODELIVERY SCIENCES INTERNATIONAL INC - REDUCES ANNUAL INTEREST COSTS BY APPROXIMATELY $1.5 MILLION.BIODELIVERY SCIENCES INTERNATIONAL - NEW FACILITY CONSISTS OF A $60.0 MILLION TERM LOAN.BIODELIVERY SCIENCES - PROCEEDS FROM FINANCING, AVAILABLE CASH ON HAND, USED TO REPAY & RETIRE EXISTING TERM LOAN WITH CRG SERVICING LLC.

Biodelivery Sciences Q1 Loss Per Share $0.05

May 6 (Reuters) - BioDelivery Sciences International Inc <BDSI.O>::BIODELIVERY SCIENCES REPORTS STRONG FIRST QUARTER 2019 RESULTS AND RAISES BELBUCA® FULL-YEAR EXPECTATIONS.Q1 LOSS PER SHARE $0.05.Q1 REVENUE $19.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $19.3 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.SEES FY 2019 SALES $92 MILLION TO $100 MILLION.RAISES FULL-YEAR BELBUCA NET SALES EXPECTATIONS TO $83 - $88 MILLION.FY2019 REVENUE VIEW $94.6 MILLION -- REFINITIV IBES DATA.REITERATED EXPECTATION TO HAVE POSITIVE CASH FLOW FROM OPERATIONS BY YEAR END.

Biodelivery Sciences International Announces Pricing Of Public Offering Of Common Stock

April 11 (Reuters) - BioDelivery Sciences International Inc <BDSI.O>::BIODELIVERY SCIENCES INTERNATIONAL, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING PRICED AT $5.00PER SHARE.

Biodelivery Sciences International Will Not Receive Any Of Proceeds From Sale Of Shares Of Common Stock By Selling Stockholder

April 10 (Reuters) - BioDelivery Sciences International Inc <BDSI.O>::BIODELIVERY SCIENCES INTERNATIONAL, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.BIODELIVERY SCIENCES INTERNATIONAL INC - BDSI WILL NOT RECEIVE ANY OF PROCEEDS FROM SALE OF SHARES OF COMMON STOCK BY SELLING STOCKHOLDER..

Biodelivery Sciences Acquires U.S. Commercial Rights To Symproic

April 10 (Reuters) - BioDelivery Sciences International Inc <BDSI.O>::BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO SYMPROIC®.BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO SYMPROIC®.BIODELIVERY SCIENCES INTERNATIONAL INC - TOTAL 2019 COMPANY NET SALES EXPECTED TO BE $92-$100 MILLION WITH SYMPROIC NET SALES OF $7-$9 MILLION.BIODELIVERY SCIENCES INTERNATIONAL INC - WILL PAY SHIONOGI, INC., AN INITIAL PAYMENT OF $20 MILLION AND AN ADDITIONAL $10 MILLION IN SIX MONTHS.BIODELIVERY SCIENCES INTERNATIONAL INC - SHIONOGI IS ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS BASED ON NET SALES OF SYMPROIC.BIODELIVERY SCIENCES INTERNATIONAL INC - COMPANY HAS REAFFIRMED ITS EXPECTATION TO BECOME OPERATING CASH FLOW POSITIVE BY END OF 2019..BIODELIVERY SCIENCES INTERNATIONAL INC - EXPECTS LONG-TERM NET SALES POTENTIAL OF ITS PRODUCT PORTFOLIO TO BE IN RANGE OF $325 - $400 MILLION.BIODELIVERY SCIENCES INTERNATIONAL INC - EXPECT TO SEE AN ACCRETIVE CONTRIBUTION TO CASH FLOW IN FIRST HALF OF 2020 FROM SYMPROIC.

BioDelivery Sciences International Inc Increases Belbuca 2019 Net Sales Expectations To $80 Mln-$85 Mln

March 14 (Reuters) - BioDelivery Sciences International Inc <BDSI.O>::BIODELIVERY SCIENCES INTERNATIONAL INC - INCREASES BELBUCA 2019 NET SALES EXPECTATIONS TO $80-$85 MILLION.BIODELIVERY SCIENCES INTERNATIONAL INC SEES OPERATING CASH FLOW TO BECOME POSITIVE IN 2019.BIODELIVERY SCIENCES INTERNATIONAL INC - LONG-TERM POTENTIAL FOR BELBUCA NET SALES BELIEVED TO BE $250-$300 MILLION.BIODELIVERY SCIENCES INTERNATIONAL - TOTAL NET REVENUE FOR Q4 $18.0 MILLION VERSUS $14.2 MILLION IN Q3 OF 2018.BIODELIVERY SCIENCES INTERNATIONAL INC QTRLY LOSS PER SHARE $0.10.BIODELIVERY SCIENCES INTERNATIONAL INC SEES 2019 TOTAL COMPANY NET REVENUE TO BE IN RANGE OF $85-$90 MILLION.BIODELIVERY SCIENCES INTERNATIONAL - AT DECEMBER 31, 2018, CASH AND CASH EQUIVALENTS OF APPROXIMATELY $43.8 MILLION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up